ArticleAdvances in therapy2026

Efficacy and Safety of EG12014 (Biosimilar Trastuzumab) Compared to Reference Trastuzumab in HER2-Positive Early Breast Cancer: A Phase III Randomized Study.

Chiun-Sheng Huang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.